Last updated: September 5, 2026
Oltipraz is an investigational synthetic dithiolethione that has been studied primarily for cancer chemoprevention, aflatoxin-related hepatocellular carcinoma risk, and selected gastrointestinal indications. It is not FDA-approved, has no established commercial product, no Orange Book-listed drug product, and no validated launch timeline. The most credible development path is a renewed biomarker-driven prevention program in populations exposed to aflatoxin, but the commercial case remains unproven.
What is the current development status of oltipraz?
Oltipraz has not reached an approved clinical indication. Its development has largely remained in early- and mid-stage clinical research rather than advancing into a registrational program.
| Attribute |
Oltipraz status |
| Active ingredient |
Oltipraz, also known as 4-methyl-5-pyrazinyl-1,2-dithiole-3-thione |
| Drug class |
Synthetic dithiolethione; chemopreventive agent |
| Primary mechanism |
Induction of NRF2-regulated and phase II detoxification pathways |
| Lead historical use |
Prevention of aflatoxin-induced carcinogenesis |
| FDA approval |
None |
| FDA-approved indication |
None |
| Orange Book listing |
None identified |
| Commercial launch |
None |
| Biosimilar relevance |
None; oltipraz is a small molecule |
| Development stage |
Investigational; no active late-stage commercial program established |
| Principal development rationale |
Reduction of carcinogen exposure biomarkers and cancer risk |
| Main commercial barrier |
Prevention trials require large populations, long follow-up, and clinically meaningful cancer-risk evidence |
Oltipraz has been evaluated because it can activate cellular defense systems involved in carcinogen metabolism. The drug has been associated with induction of glutathione-related enzymes and other detoxification pathways regulated through NRF2 signaling. That mechanism remains biologically relevant, but biomarker improvement has not established a marketable preventive therapy.
What clinical indications have been studied for oltipraz?
Aflatoxin-related liver cancer prevention
The strongest historical rationale for oltipraz is prevention of hepatocellular carcinoma in people exposed to aflatoxin, particularly in regions where contaminated food products and chronic hepatitis B infection increase liver cancer risk.
Clinical studies in China evaluated oltipraz in individuals with measurable aflatoxin exposure. Regimens included intermittent weekly dosing and higher daily dosing. The studies reported reductions in urinary biomarkers associated with aflatoxin exposure and metabolic activation. The results supported target engagement and a chemoprevention hypothesis, but they did not establish a reduction in liver cancer incidence.
The principal development challenge is the difference between a biomarker endpoint and a clinical outcome. A registrational program would likely need to show a durable reduction in precancerous lesions, hepatocellular carcinoma incidence, or another accepted surrogate that regulators consider reasonably likely to predict clinical benefit.
Colorectal adenoma and gastrointestinal chemoprevention
Oltipraz has also been investigated in gastrointestinal chemoprevention, including studies involving colorectal adenomas or populations at increased colorectal cancer risk. These programs sought to determine whether enzyme induction could reduce recurrent adenomas or other premalignant changes.
The gastrointestinal prevention pathway has not produced an approved product. The field also faces competition from aspirin, nonsteroidal anti-inflammatory drugs, surveillance colonoscopy, polypectomy, and newer molecularly targeted prevention strategies.
Other exploratory uses
Oltipraz has appeared in broader experimental research involving oxidative stress, carcinogen detoxification, and cellular stress responses. These studies do not establish a clinical development program. No evidence supports positioning oltipraz as an approved treatment for cancer, liver disease, inflammatory disease, or infectious disease.
What is the FDA regulatory status of oltipraz?
Oltipraz has no FDA-approved application, approved label, or recognized commercial indication. It is absent from the FDA Orange Book as an approved drug product.
The regulatory path would likely be a new drug application based on a prevention indication, not an abbreviated new drug application. Because oltipraz is not an approved reference product, a generic applicant could not rely on the ordinary ANDA pathway to market it in the United States. A sponsor would need to establish safety, pharmacology, manufacturing quality, and efficacy under an investigational new drug and new drug application framework.
Potential regulatory routes include:
- A conventional drug-development program for a defined high-risk population.
- A biomarker-supported prevention program if the FDA accepts the biomarker as a surrogate endpoint.
- A rare-disease or geographically targeted prevention strategy if the sponsor can define a sufficiently concentrated high-risk population.
- A combination approach with hepatitis B vaccination, antiviral therapy, food-safety measures, or cancer surveillance.
The most plausible FDA challenge would be clinical endpoint selection. A reduction in aflatoxin-DNA adducts or urinary metabolites may demonstrate pharmacodynamic activity but may not be sufficient for approval.
When could oltipraz lose exclusivity?
Oltipraz has no current U.S. product exclusivity because it has no approved product. Any foundational composition-of-matter patents would have been filed decades ago and would ordinarily have expired by now, absent unusual patent-term adjustments or later-issued, enforceable claims.
| Exclusivity category |
Current assessment |
| U.S. composition-of-matter patent |
Any early patent protection would generally be expired |
| U.S. method-of-use patents |
Historical claims may exist, but no current commercial exclusivity is established |
| Formulation patents |
No commercially relevant, active formulation estate is established |
| FDA chemical exclusivity |
None |
| Orphan-drug exclusivity |
None identified |
| Pediatric exclusivity |
None |
| Orange Book patent listing |
None |
| Paragraph IV exposure |
No meaningful Orange Book Paragraph IV pathway currently exists |
A future sponsor could seek patents on a new formulation, dosing regimen, combination therapy, patient-selection biomarker, or specific prevention method. Those rights would protect only the claimed invention and would not recreate broad exclusivity over the old active ingredient.
What patents protect oltipraz?
The commercially relevant patent position appears weak for the active ingredient itself. Oltipraz was discovered and clinically investigated during the 1980s and 1990s, placing any early compound patents well beyond the ordinary 20-year term measured from the earliest effective nonprovisional filing.
The potential sources of future patent value are narrower:
Formulation patents
A sponsor could pursue claims covering improved oral bioavailability, modified release, reduced gastrointestinal toxicity, increased stability, or a combination with a delivery system. Such patents would need to provide a genuine technical improvement over conventional oral oltipraz.
Method-of-use patents
Possible claim categories include use in:
- Adults with high aflatoxin exposure.
- Patients with chronic hepatitis B and elevated hepatocellular carcinoma risk.
- Genetically selected patients with impaired detoxification pathways.
- Prevention of specific premalignant gastrointestinal lesions.
- Combination prevention with antiviral therapy or nutritional intervention.
Method-of-use patents would face enablement, written-description, obviousness, and clinical-relevance challenges. A patent based only on the historical observation that oltipraz induces detoxification enzymes would likely have limited strength.
Manufacturing and process patents
Process patents could cover impurity control, scalable synthesis, polymorph selection, particle engineering, or pharmaceutical-grade production. Manufacturing claims may create supply-chain leverage but would not prevent all competing production unless the protected process is difficult to design around.
How strong is the oltipraz patent estate?
The estate is weak as a standalone commercial barrier and potentially moderate only if a sponsor develops a new, patentable clinical package.
| Patent asset |
Commercial strength |
| Original active-ingredient claims |
Low, because historical protection is likely expired |
| Broad cancer-prevention claims |
Low to moderate, depending on claim scope and prior art |
| Biomarker-selected population claims |
Moderate if supported by clinical data |
| New formulation claims |
Moderate if the formulation solves a documented problem |
| Manufacturing claims |
Moderate for supply protection; limited against alternative processes |
| Combination claims |
Moderate, with validity dependent on unexpected clinical benefit |
| Data exclusivity |
None before approval |
| Freedom to operate |
Generally more favorable for the old compound than for any new formulation or combination |
The absence of an active broad patent estate reduces licensing barriers but also reduces commercial incentive. A sponsor would likely need a new intellectual-property package before investing in a large prevention program.
Are there Paragraph IV challenges or patent litigation involving oltipraz?
No material U.S. Paragraph IV dispute is associated with oltipraz because there is no approved reference-listed drug and no Orange Book patent listing. No significant current patent litigation or settlement agreement is established as part of an active U.S. commercial launch program.
Historical research collaborations, institutional rights, or compound-development agreements may have existed, but they do not create current market exclusivity unless supported by active contractual, patent, or regulatory rights. Oltipraz has not generated the type of litigation record associated with marketed oncology products.
What is the biosimilar and generic risk for oltipraz?
Biosimilar risk is irrelevant because oltipraz is a chemically synthesized small molecule. Generic risk would become significant if a sponsor obtained approval without strong formulation, method-of-use, or regulatory exclusivity.
A future approved oltipraz product could face several types of competition:
- An authorized generic or conventional generic after applicable exclusivity ends.
- Competing chemoprevention agents.
- Antiviral treatment for hepatitis B.
- Hepatitis B vaccination.
- Food-safety interventions that reduce aflatoxin exposure.
- Endoscopic surveillance and removal of premalignant lesions.
- Other NRF2 activators or detoxification-inducing agents.
The greatest competitive threat would come from prevention strategies that reduce the underlying carcinogen exposure rather than from a chemically similar generic.
What is the market projection for oltipraz?
Oltipraz has no established revenue base, product forecast, or approved market. A defensible projection must therefore be scenario-based rather than a conventional prescription-sales forecast.
Addressable population
The theoretical population is large. Aflatoxin exposure affects parts of sub-Saharan Africa, Southeast Asia, South Asia, and other regions where food contamination and limited storage controls increase exposure. The commercially relevant population is much smaller because treatment would likely be limited to individuals with:
- Persistent or high aflatoxin exposure.
- Elevated hepatocellular carcinoma risk.
- Adequate diagnostic and monitoring access.
- Sufficient adherence to long-term preventive therapy.
- A health system capable of paying for a chronic prevention product.
Revenue scenarios
| Scenario |
Development assumption |
Commercial outcome |
| Downside |
Biomarker effects do not translate into clinical benefit |
No approval; negligible product revenue |
| Base case |
Approval in a defined high-risk population with limited payer coverage |
Small specialty or public-health market |
| Upside |
Demonstrated reduction in liver cancer incidence and adoption in multiple high-risk countries |
Regional prevention product with potentially meaningful institutional sales |
| Breakout case |
Broad label covering aflatoxin-related cancer risk and selected liver-disease populations |
Larger global market, but still constrained by low pricing in endemic regions |
A premium oncology-prevention price would be difficult to sustain in the countries with the greatest aflatoxin burden. The strongest commercial model would probably involve public-health procurement, development finance, government programs, and partnerships with food-safety or liver-cancer prevention initiatives.
Oltipraz would need a clear economic advantage over exposure reduction, hepatitis B vaccination, antiviral therapy, cancer surveillance, and nutritional interventions. Demonstrating biomarker activity alone would not support a large commercial forecast.
How does oltipraz compare with competing prevention strategies?
| Strategy |
Development status |
Commercial advantage |
| Oltipraz |
Investigational |
Direct pharmacologic reduction of carcinogen activation |
| Hepatitis B vaccination |
Established preventive intervention |
Broad population benefit and strong public-health infrastructure |
| Antiviral therapy |
Approved for chronic hepatitis B |
Reduces viral-driven liver disease and cancer risk |
| Food-safety controls |
Public-health intervention |
Reduces exposure before carcinogenesis occurs |
| Surveillance and early detection |
Established in selected populations |
May improve outcomes without chronic preventive dosing |
| Other NRF2 activators |
Research-stage or limited clinical development |
Potentially broader or more modern formulation platforms |
Oltipraz’s differentiation would depend on proving benefit in people who remain exposed despite food-safety measures or who carry multiple risk factors, including aflatoxin exposure and chronic hepatitis B.
What development milestones would be required for a commercial launch?
A sponsor would need to establish:
- A validated patient population with measurable cancer risk.
- A commercially scalable and pharmaceutically robust formulation.
- Dose selection that balances enzyme induction with tolerability.
- A regulatory endpoint acceptable for prevention.
- Long-term safety data for chronic administration.
- Evidence that biomarker changes predict reduced cancer incidence.
- A manufacturing process with controlled impurities and reproducible quality.
- A reimbursement model for endemic markets.
- New patent claims covering formulation, patient selection, dosing, or combination use.
- Regional partnerships capable of reaching high-risk populations.
Without these elements, the asset remains a research compound rather than a near-term pharmaceutical product.
Key Takeaways
- Oltipraz is an investigational chemoprevention compound with no FDA approval or commercial launch.
- Its strongest historical use case is prevention of aflatoxin-related hepatocellular carcinoma.
- Clinical evidence has supported biomarker modulation but has not established a reduction in cancer incidence.
- There is no meaningful current Orange Book, Paragraph IV, biosimilar, or U.S. patent-litigation pathway.
- Original compound protection is likely expired; future value would depend on new formulation, biomarker, combination, or manufacturing patents.
- The addressable population may be large, but the paying market is concentrated in high-risk groups and public-health systems.
- The base commercial case is a limited regional prevention product, not a conventional high-price oncology launch.
- The main investment risk is clinical and regulatory: proving that biomarker improvement produces a clinically accepted prevention benefit.
FAQs About Oltipraz Development and Commercial Potential
Is oltipraz approved for liver cancer prevention?
No. Oltipraz is not approved by the FDA or established as a standard preventive therapy for hepatocellular carcinoma.
Can a generic company launch oltipraz immediately?
No. There is no approved U.S. reference-listed oltipraz product for an ordinary ANDA launch. A company would need to pursue its own regulatory approval.
Does oltipraz have orphan-drug exclusivity?
No current orphan-drug exclusivity is established for oltipraz.
Is oltipraz a competitor to sorafenib or lenvatinib?
No. Sorafenib and lenvatinib are treatments for advanced hepatocellular carcinoma, while oltipraz has been studied as a preventive agent. They address different clinical stages.
What would make oltipraz commercially investable?
The key value drivers would be a controlled clinical trial showing reduced cancer risk, an FDA-acceptable prevention endpoint, a tolerable chronic-dose formulation, and new enforceable patents around patient selection or product design.
References
-
Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.
-
ClinicalTrials.gov. (n.d.). Search results for oltipraz clinical studies. U.S. National Library of Medicine.
-
Kensler, T. W., Groopman, J. D., Roebuck, B. D., Curphey, T. J., & Headey, J. E. (1999). Development of cancer chemopreventive agents: Oltipraz as a paradigm. Chemical Research in Toxicology, 12(2), 113-126.
-
Wang, J. S., Shen, X., He, X., Zhu, Y. R., Zhang, B. C., Wang, J. B., Qian, G. S., Kuang, S. Y., Zarba, A., Egner, P. A., Jacobson, L. P., Munoz, A., Helzlsouer, K. J., Groopman, J. D., & Kensler, T. W. (1999). Protective alterations in phase 1 and phase 2 metabolism of aflatoxin B1 by oltipraz in residents of Qidong, People’s Republic of China. Journal of the National Cancer Institute, 91(4), 347-354.
-
National Cancer Institute. (n.d.). Oltipraz. Division of Cancer Prevention, U.S. National Institutes of Health.
-
U.S. Food and Drug Administration. (2023). Investigational new drug application process. Center for Drug Evaluation and Research.
